This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website

close x

You are now leaving!

OTEZLA delivers efficacy in DMARD-naïve patients1



treatment in dmard‐naïve patients
all manifestations of psoriatic arthritis

PALACE 4 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.

OTEZLA monotherapy also effectively relieves preexisting dactylitis and enthesitis in DMARD-naïve patients1,2*

  • At 3 years, among patients receiving OTEZLA, 84.5% achieved complete resolution of dactylitis and 63.3% achieved complete resolution of enthesitis
  • During the placebo-controlled phase, at week 16, percent change in dactylitis count was -69.2% with OTEZLA 30 mg BID vs -50.0% for placebo (P = 0.1494); percent change in MASES (enthesitis) score was -50% vs 0%, respectively (P = 0.0008)

Patients with enthesitis and dactylitis at baseline: OTEZLA 30 mg BID, 63.1% (111/176) and 47.7% (84/176), respectively; placebo, 65.3% (115/176) and 51.1% (90/176), respectively.

Data as observed.

BL, baseline; DMARD, disease-modifying antirheumatic drugs; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.

References: 1. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast Monotherapy as the First Systemic Treatment in DMARD-Naïve Patients With Psoriatic Arthritis: 3-Year Treatment Results. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2. Edwards C, Wells A, Adebajo A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial. Ann Rheum Dis. 2014;73:735.

Select an e-mail client to share

close x